Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mirum Pharmaceuticals, Inc.

https://mirumpharma.com

Latest From Mirum Pharmaceuticals, Inc.

First-Of Kind BMS Drugs Among Myriad New Filings In EU

Marketing applications for 10 new drugs have been added to the latest list of products under review by the European Medicines Agency.

Europe Drug Review

Orphans Dominate New US FDA Approvals, Thanks To Rethymic, Tavneos, And Livmarli

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Mirum Targets $500m Sales For Just-Approved Rare Liver Disorder Drug

Regulators have approved Mirum's IBAT inhibitor as the first medication for a genetic disorder which affects up to 2,500 children in the US.

Approvals Liver & Hepatic

Asia Deal Watch: Beximco Broadens Offerings, Capabilities With Sanofi Bangladesh Buy

Plus deals involving Biosplice/Haisco, SciClone/Tarveda, Everest/Sinovent/SinoMab, Kyowa Kirin/AM-Pharma, Sandoz/Bio-Thera, Dr. Reddy’s/Citius, Jiangsu Hengrui/Mabworks, GeneQuantum/BrightGene, Innovent/GenFleet and Takeda/Mirum.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register